23andMe: What If …
A much diminished 23andMe exists today, a far cry from the phenomenon that it was in the world consumer DNA testing. Could things have unfolded differently under a different leader with a different vision?
23andMe to buy online pharmacy Lemonaid for $400M
The company plans to pair its direct-to-consumer genetic testing with Lemonaid’s online coaching and prescription delivery. It plans to buy the company for $400 million in stock and cash.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
23andMe closes out 2020 with $82.5M in funding
DNA testing company 23andMe raised $82.5 million in funding, according to a recent filing. Earlier this year, decreased sales of tests kits led to cuts at the company and its competitors.
Faced with slowing demand, 23andMe cuts 100 employees
The DNA testing company confirmed on Thursday that it would lay off about 100 employees. The restructuring was a result of slowing consumer demand.
LunaPBC is trading company shares for member health data
On the company's LunaDNA platform, a whole genome can be exchanged for 300 company shares, while 20 days of fitness data is equal to two shares.
Direct-to-consumer lab testing startup EverlyWell raises $50 million
CEO and founder Julia Cheek started EverlyWell after her own experiences trying to diagnose her own health issues highlighted problems of cost and convenience in the traditional lab testing process.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Helix and PerkinElmer launch GenePrism genetic risk product in competition with 23andMe
Helix is responsible for sequencing the user's DNA and passing results to PerkinElmer, which will provide data analysis and interpretative services using the company's team of medical geneticists.
23andMe launches new diabetes risk test, but experts are wary of its benefit
In contrast to 23andMe's previous FDA approvals for genetic risk tests for conditions like Alzheimer's, the diabetes assessment did not go through the FDA clearance pathway because it was characterized as a wellness product not intended to make diagnoses and provide medical advice.
23andMe gets FDA nod for new Colorectal cancer indication test
The company used its previous authorization for breast cancer genetic screening as a predicate for its 510(k) approval.
FDA approves 23andMe pharmacogenetics test for 33 drug metabolism-related genetic variants
The test, which the company will sell directly to consumers, is designed to find whether patients metabolize drugs quickly or slowly.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
An App Store for genomics
Helix, based near San Francisco, touts its API-based business model as a way to stand out among the plethora of personal genomics companies.
Rock Health: Digital health investing has already surpassed record-breaking 2017
In 2018 alone, ten companies have inked mega-deals of more than $100 million including Livongo, 23andMe and American Well.
Building a company from scratch: 23andMe, athenahealth and Evolent Health CEOs on entrepreneurship
Shocker, shocker — healthcare is challenging. At HLTH, CEOs Anne Wojcicki, Jonathan Bush and Frank Williams discussed how they persevered and made their companies succeed in a difficult sector.
FDA gives nod to 23andMe for no-prescription breast cancer gene testing
The Food and Drug Administration has granted 23andMe the first-ever authorization for direct-to-consumer genetic testing for cancer risk without a prescription.
A 23andMe study of genomics and weight loss seeks pathway to personalized plans to peel pounds
23andMe's weight loss study reflects the company's push to refine genomic tests by identifying genetic determinants of various diseases and chronic conditions. The study also dovetails with other companies that want to take on the country's weight management challenge with genetic testing.